Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 134

1.

The Spectrum of Thrombin in Acute Coronary Syndromes.

Giri S, Jennings LK.

Thromb Res. 2015 Feb 21. pii: S0049-3848(15)00085-7. doi: 10.1016/j.thromres.2015.02.013. [Epub ahead of print] Review.

PMID:
25764910
2.

New oral anticoagulants and perioperative management of anticoagulant/antiplatelet agents.

Rahman A, Latona J.

Aust Fam Physician. 2014 Dec;43(12):861-6.

PMID:
25705736
3.

Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?

Huber K, Bates ER, Valgimigli M, Wallentin L, Kristensen SD, Anderson JL, Lopez Sendon JL, Tubaro M, Granger CB, Bode C, Ohman EM, Steg PG.

Am Heart J. 2014 Nov;168(5):611-21. doi: 10.1016/j.ahj.2014.06.014. Epub 2014 Jun 26. Review.

PMID:
25440788
4.

Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease.

Thompson PL, Verheugt FW.

Clin Ther. 2014 Sep 1;36(9):1176-81. doi: 10.1016/j.clinthera.2014.08.010.

PMID:
25234549
5.

Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications.

Trujillo T, Dobesh PP.

Drugs. 2014 Sep;74(14):1587-603. doi: 10.1007/s40265-014-0278-5. Erratum in: Drugs. 2014 Oct;74(15):1837.

6.

[Historical and future perspective of antithrombotic agents].

Goto S.

Nihon Rinsho. 2014 Jul;72(7):1193-7. Review. Japanese.

PMID:
25163307
7.

Antithrombotics in atrial fibrillation and coronary disease.

Velagapudi P, Turagam MK, Agrawal H, Mittal M, Kocheril AG, Aggarwal K.

Expert Rev Cardiovasc Ther. 2014 Aug;12(8):977-86. doi: 10.1586/14779072.2014.937427. Review.

PMID:
25046150
8.

Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives.

Turpie AG.

Expert Rev Cardiovasc Ther. 2014 Aug;12(8):963-76. doi: 10.1586/14779072.2014.938055. Epub 2014 Jul 12. Review.

PMID:
25017622
9.
10.

Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice.

Shivu GN, Ossei-Gerning N.

Vasc Health Risk Manag. 2014 May 12;9:291-302. doi: 10.2147/VHRM.S59420. eCollection 2014. Review.

11.

Direct oral anticoagulants in acute coronary syndrome.

Ahrens I, Bode C.

Semin Hematol. 2014 Apr;51(2):147-51. doi: 10.1053/j.seminhematol.2014.03.004. Epub 2014 Mar 29.

PMID:
24861799
12.
13.

The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.

Reddy P, Giugliano RP.

J Cardiovasc Pharmacol Ther. 2014 Nov;19(6):526-32. doi: 10.1177/1074248414525505. Epub 2014 Mar 21.

PMID:
24659084
14.

Peri-operative management of anticoagulation and antiplatelet therapy in gastrointestinal surgery.

Degirmenci SE, Steib A.

J Visc Surg. 2014 Apr;151(2):125-35. doi: 10.1016/j.jviscsurg.2014.01.009. Epub 2014 Mar 14. Review.

PMID:
24631468
15.

Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions.

Capodanno D, Angiolillo DJ.

Circ Cardiovasc Interv. 2014 Feb;7(1):113-24. doi: 10.1161/CIRCINTERVENTIONS.113.001150. Review. No abstract available.

16.

Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome.

Ice DS, Shapiro TA, Gnall EM, Kowey PR.

Am J Cardiol. 2014 Mar 1;113(5):888-96. doi: 10.1016/j.amjcard.2013.11.046. Epub 2013 Dec 12. Review.

PMID:
24528617
17.

Anticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decade.

Atar D, Bode C, Stuerzenbecher A, Verheugt FW.

Fundam Clin Pharmacol. 2014 Aug;28(4):353-63. doi: 10.1111/fcp.12063. Epub 2014 Mar 10. Review.

18.

Management of acute coronary syndrome in patients with non-valvular atrial fibrillation: results of the European Heart Rhythm Association Survey.

Potpara TS, Lip GY, Dagres N, Estner HL, Larsen TB, Blomström-Lundqvist C; Conducted by the Scientific Initiatives Committee, European Heart Rhythm Association.

Europace. 2014 Feb;16(2):293-8. doi: 10.1093/europace/euu008.

19.

Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.

Cheng JW, Barillari G.

J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Epub 2014 Jan 3. Review.

PMID:
24383983
20.

Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes.

Ganetsky VS, Hadley DE, Thomas TF.

Pharmacotherapy. 2014 Jun;34(6):590-604. doi: 10.1002/phar.1375. Epub 2013 Dec 13. Review.

PMID:
24338703
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk